RUNX3 and neoplasm: The current analyses comprising all eligible articles revealed that promoter methylation of the p16, CDH1, RUNX3, MLH1, RASSF1A, p15, APC, GSTP1, Reprimo, and MGMT was significantly higher in blood samples of patients with GC compared with non-tumor controls.